The capacity of loss of CDX2—a differentiation-inducing transcription factor—to cooperate with the BRAF mutant to promote intestinal cell transformation is not surprising since CDX2 abnormalities have been associated with BRAF-driven serrated tumor development [85,86,87]. This evidence concerns the gene CDX2 and neoplasm.